crossorigin="anonymous">A study showed that the initial safety findings

Reports of serious adverse events among children receiving a new booster shot using the updated COVID-19 vaccine are very rare.

A study showed that the initial safety findings for the new coronavirus booster shot were reassuring.

A child is given her Covid-19 vaccination by a nurse. At the Santa Clara County Fairgrounds in San Jose, CA, on June 21, 2022. According to the Centers for Disease Control have stated that serious incidents following the booster shots for children’s COVID-19 are extremely rare.

One Million New Cases

A new study of safety information by the Centers for Disease Control and Prevention discovered. Only two instances of serious adverse events in the wake of the more than 1 million new COVID-19 booster shots. That were administered to children between the ages of 5 and 11 since October.

Vaccination Mistakes

This study that was released on Thursday by the CDC it analyzed more than 900 complaints submitted to the Vaccine. Adverse Event Reporting System and discovered that 99.8 percent of reports for children. Between the ages of 5-11 were deemed to not be serious. A majority of the complaints were related to vaccination mistakes such as children being given the incorrect dose for their age.

The two major events that were reported included one child that developed symptoms that are consistent to Miller Fisher syndrome. Which is a rare neurologic condition which is thought to be a variation that is a variant of Guillain-Barre Syndrome. As well as another child was admitted to hospital with arthritis and hives.

safety findings
safety findings

Safety Surveillance

Researchers also examined the more than 3200 submitted submissions for v-safe the safety surveillance system. Created by CDC to monitor adverse reactions following COVID-19 vaccination. They discovered that none of the children within the program were given medical attention following vaccination using the latest shot.

In addition, there were no cases of myocarditis or even death were reported following the shot.

The study stated, booster vaccinations in children between the ages of 5 and 11 are encouraging. Preliminary safety results in the initial 11 weeks following bivalent.

Latest Booster Shots

The Food and Drug Administration approved the latest booster shots for children starting at age 5 in October, citing concerns about “increased chance of exposure” in the wake of children returning to school. The shots target subvariants of omicron BA.4 and BA.5 and the coronavirus strain that was originally identified.

However, as various variations of COVID-19 have taken place and more children.
While it’s been the scenario in the past that COVID-19 is less severe in children than in adults have been sick and were hospitalized,” the FDA’s top official for vaccines, Peter Marks, said at the time.
 “Children could also be suffering longer-term consequences, even after the initial mild symptoms. Parents are encouraged to think about an initial vaccination for their children and to follow-up with an up-to-date booster dose if they are you are eligible.”

Safety Finding

Since the vaccine’s approval, less than one million children from the 5-11 age bracket have received the vaccine as per CDC statistics. That’s around 2% of total number of booster shots that were updated that were administered in the last week. This is the reason why Biden Administration has been campaigning for for the updated shot in anticipation of the possibility of switching to an the annual COVID-19 booster program.


2 thoughts on “Reports of serious adverse events among children receiving a new booster shot using the updated COVID-19 vaccine are very rare.

  1. I am a student of BAK College. The recent paper competition gave me a lot of headaches, and I checked a lot of information. Finally, after reading your article, it suddenly dawned on me that I can still have such an idea. grateful. But I still have some questions, hope you can help me.

Leave a Reply

Your email address will not be published. Required fields are marked *